Shots:

• The P-III trial evaluates a booster dose of COVID-19 vaccine (30µg) in a ratio (1:1) in 10000+ individuals aged ≥16yrs. with COVID-19 who previously received the primary two-dose series of vaccine
• The results showed vaccine efficacy of 95.6% compared to a non-boosted group- median time b/w second & booster dose was ~11mos.- symptomatic COVID-19 occurrence was measured from 7 days after booster with a median follow-up of 2.5mos.- AEs profile was consistent with other clinical safety data for vaccine & no safety concerns were observed
• The companies also plan to share the data with the US FDA- EMA & other regulatory agencies globally to support license in the US & other countries shortly

Ref: Pfizer | Image: Hindustan Times